Peter David, Ph.D. is the Chief Science Officer and a founder of BioDTX. He currently serves as a consultant to several venture capital firms and as an advisor to startups. Peter is an inventor of a number of scientific techniques and instruments. Before co-founding BioDTX, he was a researcher at Stanford University. He received a B.A. in chemistry and mathematics from Oberlin College and an M.A. and Ph.D. in physical chemistry from Harvard University. During postgraduate studies, Peter developed a novel program for computer directed drug design and then founded the team that solved the x-ray structure of yeast RNA polymerase II.

Jonathan Dugan, Ph.D., is founder and CEO of Matson Systems, a software startup building web-based collaboration tools.

Jonathan has worked as a consultant providing business strategy and technical implementation on the topic of building and maintaining community.

Shauna Farr-Jones currently consults for biotechnology companies doing technology assessment, competitive intelligence, grant proposal writing and market research. She also helps academics and non-profits to prepare complex multi-investigator grant and contract proposals. She was recently at BioCentury Publications, the leading biotechnology business newsletter, where she analyzed and wrote about strategic market and technology issues affecting biotechnology companies. Her scientific interests include drug discovery technologies, structural biology and bioinformatics. Shauna's education includes a post-doctoral fellowship at UCSF, Ph.D. in Biochemistry from Tufts University in Boston, and a B.Sc. in Chemistry from Southampton University, UK.

Carrie Kahn, PhD, is the Founder and CEO of Sensorin, an emerging company that has developed a novel platform technology. Its’ first product will provide calibration free pH sensing capability to the biologics manufacturing industry. Prior to this venture Carrie served as President and CEO of Hepaticus, which was developing an animal model for ADMET and HCV drug development. This venture emerged from the BioSeed Fund that Carrie founded while serving as an early stage venture investor with Connecticut Innovations (CI). While at CI she invested and served on the board of a number of early stage companies, and also helped create and manage a $60 million BioTech Facilities Fund to provide facility improvements to portfolio companies. Following years of academic research, and prior to becoming involved in entrepreneurial activities, she developed an in vitro model of the human cornea to avoid animal based ocular safety testing while working for the Gillette Medical Evaluation Labs at the Gillette Corporation. Carrie received her degrees from the Johns Hopkins University (AB) and the Johns Hopkins School of Medicine (PhD).

Lesley Pickford is a consultant in biotechnology R&D, advising small and startup companies on strategies for defining their preclinical programs, product profiles and target markets. Lesley has over 12 years industry experience in the Bay Area in bio-pharmaceutical and diagnostics development, predominantly in the disease areas of oncology, autoimmune diseases and metabolic disorders. Until mid-2003, Lesley was VP of Research at Calyx Therapeutics and previously she held Director of Pharmacology and/or Toxicology positions at the biopharmaceutical companies Corixa, Coulter Pharmaceutical and Connetics. Lesley has lead and participated on many project teams, including collaborative joint ventures with international pharmaceutical companies. She has been extensively involved in Business Development activities including M&A, licensing of drugs and spin-outs of research programs.

Lesley received a PhD in Medical Biochemistry from Flinders University of South Australia, and a Bachelors of Science degree from Adelaide University, in South Australia. She held Post-Doctoral Fellowships at Stanford University in the Departments of Pathology and Psychiatry for 6 years, working on neuro-immunology and ageing projects.

Dr. Sherman-Gold holds a B.Sc. in chemistry and M.Sc. in biophysics and physiology, both from the Technion - Israel Institute of Technology, Ph.D. in life-science from The Weizmann Institute of Science, and M.B.A. from California State University, San Jose (SJSU). She was a post-doctoral fellow at Stanford University School of Medicine.

Prior to practicing law, Dr. Wong conducted doctoral and post-doctoral research at Harvard and Tufts Medical School in a multidisciplinary area combining molecular biology, cell biology, and physiology. She received her B.A. in Molecular, Cellular and Developmental Biology from the University of Colorado-Boulder. Dr. Wong also holds a J.D. from Santa Clara University School of Law.

With the formation of GSK, Stuart was appointed to a new business development position within International Operations Region, based in the UK. Stuart’s focus was on markets in the Asian Pacific Region where he led numerous projects in China, India and Korea, in addition to Japan.